Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD20

CD20

Check out full-length Claudin 18.2, CD20 and more.

Brief Information

Name:B-lymphocyte antigen CD20
Target Synonym:B-lymphocyte surface antigen B1,MS4A1,B-lymphocyte antigen CD20,Membrane Spanning 4-Domains A1,Leukocyte Surface Antigen Leu-16,CD20 Antigen,CD20,Bp35,Membrane-Spanning 4-Domains Subfamily A Member 1,CD20 Receptor,LEU-16,CVID5,MS4A2,B1,S7,Antigens, CD20,Membrane-Spanning 4-Domains, Subfamily A, Member 1,B-Lymphocyte Cell-Surface Antigen B1
Number of Launched Drugs:26
Number of Drugs in Clinical Trials:92
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CHEK-ATP034-Cell-based assay
 CD20 FACS

FACS assay shows that Monoclonal Anti-Human CD20 Full Length Antibody, Human IgG1 can bind to HEK293/Human CD20 Stable Cell Line. HEK293/Human CD20 Stable Cell Line was red line, Negative control HEK293 cells was grey line (QC tested).

CD0-H52H1-Cell-based assay
 CD20 FACS

2e5 of CD20-CAR-293 cells transfected with anti-CD20-scFv were stained with 100 μL of 3 μg/mL of Human CD20 / MS4A1 Full Length Protein, His Tag (Nanodisc) (HEK293)(Cat. No. CD0-H52H1) and negative control protein respectively, washed and then followed by PE anti-His antibody and analyzed with FACS (QC tested).

CD0-C52H8-SPR
 CD20 SPR

Rituximab captured on CM5 chip via anti-human IgG Fc antibody can bind Cynomolgus CD20 Full Length, His Tag (Cat. No. CD0-C52H8) with an affinity constant of 5.48 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).

CD0-C52H8-SPR
 CD20 SPR

Ofatumumab captured on CM5 chip via anti-human IgG Fc antibody can bind Cynomolgus CD20 Full Length, His Tag (Cat. No. CD0-C52H8) with an affinity constant of 3.51 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).

Customer Reviews

Synonym Name

MS4A1,CD20,MS4A-1

Background

B-lymphocyte antigen CD20  is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ofatumumab OMB-157; HuMax-CD2; GSK-1841157; 2F2 Approved Genmab A/S Arzerra, Kesimpta United States Multiple Sclerosis, Relapsing-Remitting Beijing Novartis Pharma Co Ltd 2009-10-26 Leukemia; Multiple Sclerosis, Relapsing-Remitting; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Multiple Sclerosis; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus Details
Rituximab biosimilar (Reliance Life Sciences) R-TPR-017 Approved Reliance Life Sciences Toritz, RituxiRel India Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid null 2016-01-01 Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Center of Molecular Immunology) Approved Center Of Molecular Immunology CIMAbior, RituxCIM Cuba Lymphoma, Non-Hodgkin null 2017-04-01 Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Biocad) BCD-020 Approved Biocad Acellbia Russian Federation Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin Biocad 2015-01-01 Lymphoma, B-Cell, Marginal Zone; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (mAbxience) RTXM-83; mAbx-02 Approved Mabxience Sa Novex Argentina Lymphoma, Large B-Cell, Diffuse Mabxience Sa 2015-01-01 Lymphoma, B-Cell, Marginal Zone; Anemia; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Leukemia, B-Cell; Lymphoma, T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
rituximab biosimilar (Zenotech) Approved Zenotech Laboratories India Lymphoma, Non-Hodgkin Zenotech Laboratories 2013-02-01 Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (AryoGen Biopharma) Approved Aryogen Biopharma Zytux Iran Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Granulomatosis with Polyangiitis; Microscopic Polyangiitis Aryogen Biopharma 2014-01-01 Leukemia, Myelogenous, Chronic; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Intas Biopharmaceuticals) Approved Intas Biopharmaceuticals Mabtas India Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Intas Biopharmaceuticals 2013-01-01 Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Dr Reddy's Laboratories) Approved Dr Reddy's Laboratories Ltd Reditux, Tidecron India Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid Dr Reddy's Laboratories Ltd 2007-01-01 Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Biosidus) Approved Biosidus Argentina Hematologic Neoplasms Biosidus 2013-06-01 Hematologic Neoplasms Details
Rituximab biosimilar (Hetero Drugs) Approved Hetero Drugs Ltd Maball, Mabura India Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular Hetero Drugs Ltd 2015-01-01 Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Probiomed) PBO-326 Approved Probiomed Kikuzubam Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin Details
Hyaluronidase/Rituximab Approved Genentech Inc Rituxan Hycela United States Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular Genentech Inc 2017-06-22 Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Pfizer) PF-05280586; PF-5280586 Approved Pfizer Pharmaceuticals Ltd (China) Ruxience United States Microscopic Polyangiitis; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Granulomatosis with Polyangiitis Pfizer Inc 2019-07-23 Lymphoma, T-Cell; Plasmablastic Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Leukemia, B-Cell; Lymphoproliferative Disorders; Leukemia, Myeloid, Chronic-Phase; Burkitt Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Lymphoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Biphenotypic, Acute; Pemphigus; Lymphoma, Large B-Cell, Diffuse; Bone Marrow Neoplasms; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase; Granulomatosis with Polyangiitis; Leukemia, Lymphoid; Anemia; Anemia, Refractory, with Excess of Blasts; Microscopic Polyangiitis; Lymphoma, B-Cell; Myelodysplastic Syndromes; Hodgkin Disease; Lymphoma, AIDS-Related; Leukemia, Myelomonocytic, Chronic; Arthritis, Rheumatoid; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Ocrelizumab R-1594; RG-1594; PRO-70769; RO-4964913; rhuMab 2H7 Approved Genentech Inc Ocrevus United States Multiple Sclerosis Genentech Inc 2017-03-28 Multiple Sclerosis, Relapsing-Remitting; Schizophrenia; Arthritis, Rheumatoid; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Lupus Nephritis; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Encephalitis Details
Rituximab biosimilar (Amgen) APB-798; ABP-798 Approved Amgen Inc Riabni United States Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, Follicular Amgen Inc 2020-12-17 Lymphoma, Non-Hodgkin; Lymphoma, Mantle-Cell; Plasmablastic Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Myeloid, Chronic-Phase; Lymphoproliferative Disorders; Lymphoma, Follicular; Lymphoma; Lymphoma, T-Cell; Burkitt Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Biphenotypic, Acute; Carcinoma, Non-Small-Cell Lung; Lymphoma, Large B-Cell, Diffuse; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase; Hematologic Neoplasms; Bone Marrow Neoplasms; Microscopic Polyangiitis; Anemia; Anemia, Refractory, with Excess of Blasts; Granulomatosis with Polyangiitis; Neoplasms; Hodgkin Disease; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Arthritis, Rheumatoid; Multiple Myeloma; Blastic Plasmacytoid Dendritic Cell Neoplasm Details
Ripertamab SCT-400 Approved SinoCelltech Ltd Mainland China Lymphoma, Large B-Cell, Diffuse SinoCelltech Ltd 2022-08-23 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma Details
Mosunetuzumab BTCT-4465A; RO-7030816; RG-7828 Approved Genentech Inc Lunsumio EU Lymphoma, Follicular Roche Registration Gmbh 2022-06-03 Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lupus Erythematosus, Systemic; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Obinutuzumab RG-7159; RG-7195; RO-5072759; B-HH6-B-KV1-GE; R-7159; GA-101; RG7159-7 Approved Genentech Inc Gazyva, Gazyvaro, Gazyva/Gazyvaro, 佳罗华 United States Leukemia, Lymphocytic, Chronic, B-Cell Genentech Inc 2013-11-01 Precursor Cell Lymphoblastic Leukemia-Lymphoma; Kidney Failure, Chronic; Leukemia, Lymphocytic, Chronic, B-Cell; Nephrotic Syndrome; Waldenstrom Macroglobulinemia; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Lupus Erythematosus, Systemic; Lymphoma, Mantle-Cell; Glomerulosclerosis, Focal Segmental; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lupus Nephritis; Glomerulonephritis, Membranous; Graft vs Host Disease; Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphoid; Nephrosis; Lymphoma, B-Cell; Leukemia Details
Rituximab biosimilar (Shanghai Henlius Biotech) HLX-01 Approved Shanghai Henlius Biotech Inc 汉利康 Mainland China Lymphoma, Non-Hodgkin Shanghai Henlius Biopharmaceuticals Co Ltd 2019-02-22 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Innovent Biologics) IBI-301 Approved Innovent Biologics(Suzhou) Co Ltd 达伯华, HALPRYZA Mainland China Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular Innovent Biologics(Suzhou) Co Ltd 2020-09-30 Lymphoma, Follicular; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Non-Small-Cell Lung; Burkitt Lymphoma; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, B-Cell; Leukemia, Myeloid, Chronic-Phase; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Hematologic Neoplasms; Blastic Plasmacytoid Dendritic Cell Neoplasm; Multiple Myeloma; Neoplasms; Leukemia, Myelomonocytic, Chronic; Hodgkin Disease; Myelodysplastic Syndromes; Lymphoma, Large B-Cell, Diffuse; Anemia, Refractory, with Excess of Blasts; Anemia; Leukemia, Myeloid, Accelerated Phase; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Bone Marrow Neoplasms Details
Ibritumomab tiuxetan IDEC-In2B8; BAY86-5128; SHL-749; IDEC-129; IDEC-2B8-MX-DTPA; IDEC-Y2B8 Approved Biogen Inc Zevalin, Zavalin United States Lymphoma, B-Cell Spectrum Pharmaceuticals Inc 2002-02-19 Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Ublituximab LFB-R603; TG-1303; EMAB-6; R-603; TGTX-1101; TG-1101 Approved Tg Therapeutics Inc BRIUMVI, Utuxin United States Multiple Sclerosis Tg Therapeutics Inc 2022-12-28 Lymphoma, B-Cell, Marginal Zone; Multiple Sclerosis, Relapsing-Remitting; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Multiple Sclerosis; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Neuromyelitis Optica; Lymphoma; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Celltrion) CT-P10 Approved Celltrion Inc Truxima, Blitzima, Ritemvia, Rituzena EU Microscopic Polyangiitis; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Granulomatosis with Polyangiitis Celltrion Healthcare Hungary Kft 2017-02-17 Lymphoma, Mantle-Cell; Pemphigus; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Non-Small-Cell Lung; Lymphoma; Leukemia, Myeloid, Acute; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, B-Cell; Leukemia, Myeloid, Chronic-Phase; Lymphoproliferative Disorders; Primary mediastinal B cell lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Bone Marrow Neoplasms; Lymphoma, Follicular; Multiple Myeloma; Leukemia, Myelomonocytic, Chronic; Hodgkin Disease; Myelodysplastic Syndromes; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Microscopic Polyangiitis; Leukemia, Lymphoid; Anemia, Refractory, with Excess of Blasts; Anemia; Granulomatosis with Polyangiitis; Leukemia, Myeloid, Accelerated Phase; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell Details
Rituximab R-105; RG-105; IDEC-102; IDEC-C2B8; RO-452294 Approved Biogen Inc 美罗华, Ristova, Rituxan, MabThera, MabThera/Rituxan United States Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Lymphoma, Follicular Idec Pharmaceuticals Corp, Genentech Inc 1997-11-26 Granulomatosis with Polyangiitis; Rejection of renal transplantation; Purpura, Thrombocytopenic, Idiopathic; Peripheral Nervous System Diseases; Lymphoma, B-Cell, Marginal Zone; Leukemia; Lymphoma, B-Cell; Myasthenia Gravis; Liver Cirrhosis, Biliary; Ocular Motility Disorders; Polymyositis; Diabetes Mellitus, Type 1; Opsoclonus-Myoclonus Syndrome; Multiple Sclerosis, Relapsing-Remitting; Hematologic Neoplasms; HIV Infections; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Keratoconjunctivitis Sicca; Rejection of liver transplantation; Microscopic Polyangiitis; Nephrosis; Schizophrenia; Dermatomyositis; Pulmonary Alveolar Proteinosis; Stomach Neoplasms; Myositis; Scleritis; ST Elevation Myocardial Infarction; Renal Insufficiency; Hemophilia A; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Sarcoidosis; Psychotic Disorders; Lymphoma, AIDS-Related; Lymphomatoid Granulomatosis; Autoimmune Diseases; Anemia, Diamond-Blackfan; Fatigue; Spondylitis, Ankylosing; Red-Cell Aplasia, Pure; Colonic N Details
Rituximab biosimilar (Sandoz) GP-2013 Approved Sandoz Riximyo, Rixathon EU Lymphoma, Non-Hodgkin; Microscopic Polyangiitis; Leukemia, Lymphocytic, Chronic, B-Cell; Arthritis, Rheumatoid; Granulomatosis with Polyangiitis; Pemphigus Sandoz Gmbh 2017-06-15 Lymphoma, B-Cell; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
MRG001 MRG-001 Phase 2 Clinical Shanghai Miracogen Inc Lymphoma, B-Cell; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (CTTQ Pharma) TQB-2303 Phase 3 Clinical Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd Lymphoma, B-Cell; Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Blastic Plasmacytoid Dendritic Cell Neoplasm; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Lymphoma; Lymphoma, T-Cell Details
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) Phase 2 Clinical Southwest Hospital Chongqing Lymphoma, Large B-Cell, Diffuse Details
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) Phase 1 Clinical Uclas Jonsson Comprehensive Cancer Center Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD20-CD19 cCAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics (Int'L) Ltd Lymphoma, B-Cell; Leukemia, B-Cell Details
Recombinant chimeric anti-CD20 antibody (Shanghai Institute of Biological Products) Phase 3 Clinical Shanghai Institute Of Biological Products Co Ltd Lymphoma, Large B-Cell, Diffuse Details
CAR-20-19-22 CAR-20-19-22 Phase 1 Clinical The Medical College Of Wisconsin Nonprofit Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Zamtocabtagene autoleucel MB-CART2019.1 Phase 2 Clinical Miltenyi Biotec Lymphoma, Large B-Cell, Diffuse Details
Rituximab biosimilar(Bioxpress) BXT-2336 Clinical Bioxpress Therapeutics Sa Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell Details
bbT-369 bbT-369 Phase 2 Clinical Bluebird Bio Inc Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin Details
CD19/CD20 CAR-T Cell Therapy (PersonGen) Phase 1 Clinical Persongen Biotherapeutics Details
CD19/CD20 bispecific CAR-T cells (Shanghai Cellular) Phase 2 Clinical Shanghai Cellular Biopharmaceutical Group Ltd Lymphoma, B-Cell Details
Plamotamab XmAb-13676 Phase 2 Clinical Xencor Inc Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD20 CAR-T cell therapy (Shanghai Longyao Biotechnology) Phase 1 Clinical Shanghai Longyao Biological Technology Co Ltd Lymphoma, Non-Hodgkin Details
Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein (Fred Hutchinson Cancer Research Center) Phase 1 Clinical Fred Hutchinson Cancer Research Center, National Cancer Institute Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin Details
MB-CART19.1 (Miltenyi Biotec) Phase 2 Clinical Miltenyi Biotec Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Rituximab biosimilar (International Biotech Center Generium) GNR-006 Phase 1 Clinical International Biotech Center Generium Lymphoma, B-Cell Details
Rituximab biosimilar (Gedeon Richter) RGB-03 Phase 1 Clinical Gedeon Richter Arthritis, Rheumatoid Details
Rituximab biosimilar (Samsung) SAIT-101 Phase 3 Clinical Samsung Biologics Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Leukemia, Myeloid, Acute; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoproliferative Disorders; Leukemia, Myeloid, Chronic-Phase; Leukemia, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, B-Cell; Multiple Myeloma; Blastic Plasmacytoid Dendritic Cell Neoplasm; Arthritis, Rheumatoid; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Anemia, Refractory, with Excess of Blasts; Anemia; Lymphoma, B-Cell, Marginal Zone; Bone Marrow Neoplasms; Hematologic Neoplasms; Leukemia, Myeloid, Accelerated Phase Details
Imvotamab IGM-2323 Phase 2 Clinical Igm Biosciences Inc Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
C-CAR039 EXP-039; C-CAR039; C-CAR-039 Phase 1 Clinical Cellular Biomedicine Group Ltd Lymphoma, Non-Hodgkin Details
Rituximab Biosimilar(Shanghai Institute Of Biological Products) SIBP-02 Phase 3 Clinical Shanghai Institute Of Biological Products Co Ltd Lymphoma, Large B-Cell, Diffuse Details
Rituximab biosimilar (JHL Biotech) JHL-1101 Phase 2 Clinical JHL Biotech Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Lymphoma, Follicular; Burkitt Lymphoma; Lymphoma, T-Cell; Lymphoma; Lymphoma, Non-Hodgkin Details
MB-CART20.1 (Miltenyi Biotec) Phase 1 Clinical Miltenyi Biotec Melanoma Details
TanCART19/20 Phase 1 Clinical Pla General Hospital Neuromyelitis Optica Details
Dual specificity CD19 and CD20 or CD22 CAR-T cell therapy(Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Lymphoma, B-Cell; Leukemia, B-Cell Details
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) Phase 1 Clinical First Affiliated Hospital Of Zhejiang University Lymphoma, Large B-Cell, Diffuse Details
UCART-20x22 UCART-20x22 Phase 2 Clinical Cellectis Sa Lymphoma, Non-Hodgkin Details
Anti-CD20 CART-transduced T cells (Cellular Biomedicine Group) CART-20; CBM-C20.1; CBM-CD20 1 Phase 2 Clinical Pla General Hospital Lymphoma, B-Cell; Leukemia; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma; Leukemia, Prolymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell Details
JMT-601 JMT-601 Phase 1 Clinical Shanghai Jinmante Biological Technology Co Ltd Lymphoma, Non-Hodgkin Details
BAT-4406F BAT-4406; BAT-4406F Phase 1 Clinical Bio-Thera Solutions Ltd Neuromyelitis Optica Details
Bendamustine Hydrochloride/Rituximab Phase 1 Clinical 1globe Biomedical Co Ltd Lymphoma, B-Cell Details
ADI-001 ADI-001 Phase 1 Clinical Adicet Bio Inc Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Burkitt Lymphoma Details
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Pharma) B001 Phase 1 Clinical Shanghai Pharmaceuticals Holding Co Ltd Neuromyelitis Optica; Lymphoma; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar(Shandong New Time Pharmaceutical) H-02; F-007 Phase 3 Clinical Shandong New Time Pharmaceutical Co Ltd Lymphoma, Large B-Cell, Diffuse Details
CD20-directed CAR-T cell therapy (Tongji Hospital) C-CAR066 Phase 1 Clinical Tongji Hospital Lymphoma, B-Cell Details
Allogeneic anti-CD20 CAR-T cell therapy (Precision BioSciences) PBCAR-20A Phase 2 Clinical Precision Biosciences Inc Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
EX-103 EX-103; EX103 Phase 1 Clinical Guangzhou ASM Biomedical Technology Co Ltd Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Hualan Biological Engineering) WBP-263 Phase 3 Clinical Hualan Genetic Engineering Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin Details
CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) Phase 2 Clinical Shenzhen University General Hospital Lymphoma, B-Cell Details
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) 4SCAR-T Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Hematologic Neoplasms; Autoimmune Diseases; Neuroblastoma Details
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) Phase 1 Clinical Henan Provincial Cancer Hospital Lymphoma, B-Cell Details
Anti-CD20 CAR T-cell therapy (Shanghai Longyao Biotechnology) Phase 2 Clinical Shanghai Longyao Biological Technology Co Ltd Lymphoma, Large B-Cell, Diffuse Details
Anti-CD20 CAR-T cell therapy (Wuhan Bio-Raid) Clinical Wuhan Bio-Raid Biotechnology Neoplasms Details
Ocrelizumab biosimilar (CinnaGen) Phase 3 Clinical Cinnagen Multiple Sclerosis Details
CPO-107 Phase 2 Clinical Conjupro Biotherapeutics Inc Lymphoma, Non-Hodgkin Details
IMM-0306 IMM-0306 Phase 2 Clinical ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd Lymphoma, B-Cell Details
TQB-2825 TQB-2825 Phase 1 Clinical Wuxi Biologics Co Ltd Hematologic Neoplasms; Neoplasms Details
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) Phase 1 Clinical Fujian Medical University Lymphoma, Large B-Cell, Diffuse Details
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) CAR-20/19-T cells Phase 2 Clinical The Medical College Of Wisconsin Nonprofit Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Zhejiang Teruisi Pharmaceutical) TRS001 Phase 1 Clinical Zhejiang Teruisi Pharmaceutical Inc Lymphoma Details
Rituximab biosimilar (Hisun Pharma/Beijing Mabworks Biotech) Phase 3 Clinical Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Genor Biopharma) GB-241 Phase 3 Clinical Genor Biopharma Co Ltd, Nanjing Yoko Biomedical Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Lymphoma; Leukemia, Myeloid, Acute; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Chronic-Phase; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, B-Cell; Blastic Plasmacytoid Dendritic Cell Neoplasm; Multiple Myeloma; Myelodysplastic Syndromes; Hodgkin Disease; Leukemia, Myelomonocytic, Chronic; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Anemia, Refractory, with Excess of Blasts; Bone Marrow Neoplasms; Hematologic Neoplasms; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase Details
Recombinant anti-CD20 chimeric monoclonal antibody (Livzon Group) LZM-002 Phase 1 Clinical Livzon Pharmaceutical Group Inc Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
LY007 LY007 Phase 1 Clinical Shanghai Longyao Biological Technology Co Ltd Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
Iodine 131 tositumomab TST/I131-TST Phase 3 Clinical Glaxosmithkline Plc Lymphoma, B-Cell; Leukemia, Lymphoid; Hodgkin Disease; Multiple Myeloma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) Phase 2 Clinical Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Pancreatic Neoplasms; Lymphoma, Non-Hodgkin Details
JS-203 JS-203 Phase 1 Clinical Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) Phase 1 Clinical Zhejiang University, Shanghai YaKe Biotechnology Co Ltd Hematologic Neoplasms Details
MB-106 MB-106 Phase 2 Clinical Fred Hutchinson Cancer Research Center Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell Details
Chimeric antigen receptor T-cell therapy (Fred Hutchinson Cancer Research Center) Phase 2 Clinical Fred Hutchinson Cancer Research Center Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Fred Hutchinson Cancer Research Center) Phase 1 Clinical Fred Hutchinson Cancer Research Center Lymphoma, Large B-Cell, Diffuse; Multicentric Castleman's Disease (MCD); Burkitt Lymphoma; Sarcoma, Kaposi Details
BVX20-CD20 antibody (Biocon/Vaccinex) BVX-20; BVX20-MAb Phase 2 Clinical Biocon Ltd, Vaccinex Inc Lymphoma, Non-Hodgkin Details
GB-261 GB-261 Phase 2 Clinical Genor Biopharma Co Ltd Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
LCAR-AIO LCAR-AIO; VHH CAR-T Phase 1 Clinical Nanjing Legend Biotechnology Co Ltd Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD20 monoclonal antibody(The First Affiliated Hospital of Soochow University) Phase 2 Clinical The First Affiliated Hospital Of Soochow University Anemia, Aplastic Details
Anti-CD20 allogeneic CAR-T cell therapy (Nanjing Medical University) LUCAR-20S Phase 1 Clinical Nanjing Legend Biotechnology Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell Details
QLP-31907 QLP-31907; QLP31907; PSB-202 Phase 1 Clinical Qilu Pharmaceutical Co Ltd Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab Biosimilar (Istituto Giannina Gaslini) Phase 2 Clinical Istituto Giannina Gaslini Nephrotic Syndrome Details
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Crosslink Pharmaceutical) B-007 Phase 1 Clinical Shanghai Crosslink Pharmaceutical R & D Co Ltd Nephrosis; Glomerulonephritis, Membranous; Lymphoma, Non-Hodgkin Details
Odronextamab REGN-1979 Phase 3 Clinical Regeneron Pharmaceuticals Inc Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
1-A-46 BR-110; 1A46; 1-A-46; CMG1A46; CMG1A-46; BR110 Phase 2 Clinical Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd, BioRay Pharmaceutical Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Boehringer Ingelheim) BI-695500 Phase 3 Clinical C.H. Boehringer Sohn Ag & Co. Kg Lymphoma, Mantle-Cell; Carcinoma, Non-Small-Cell Lung; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Burkitt Lymphoma; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoproliferative Disorders; Leukemia, Myeloid, Chronic-Phase; Leukemia, B-Cell; Pancytopenia; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Plasmablastic Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Blastic Plasmacytoid Dendritic Cell Neoplasm; Multiple Myeloma; Arthritis, Rheumatoid; Myelodysplastic Syndromes; Hodgkin Disease; Neoplasms; Leukemia, Myelomonocytic, Chronic; Lymphoma, Large B-Cell, Diffuse; Anemia, Refractory, with Excess of Blasts; Anemia; Bone Marrow Neoplasms; Hematologic Neoplasms; Leukemia, Myeloid, Accelerated Phase; Lymphoma, B-Cell, Marginal Zone Details
IMPT-314 IMPT-314 Phase 1 Clinical Lymphoma, B-Cell Details
RO7121932 Phase 1 Clinical Hoffmann-La Roche Inc Multiple Sclerosis Details
ACE-1831 ACE-1831 Phase 1 Clinical Acepodia Biotech Inc Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin Details
Rituximab/Bendamustine/Cytarabine Fondazione Italiana Linfomi Onlus Details
KITE-363 KITE-363 Phase 1 Clinical Kite Pharma Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse Details
CM-355(Beijing Tiannuo Jiancheng/Connaught Biomedical Technology) CM-355 Phase 2 Clinical Beijing Tiannuo Jiancheng Pharmaceutical Technology Co Ltd, Keymed Biosciences Co Ltd Hematologic Neoplasms; Hematoma; Lymphoma; Lymphoma, Non-Hodgkin Details
Recombinant humanized monoclonal antibody MIL62 MIL62 Phase 3 Clinical Beijing Innocare Pharma Tech Co Ltd, Beijing Mabworks Biotech Co Ltd Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Nephrosis; Lupus Nephritis; Glomerulonephritis, Membranous; Lymphoma, Follicular; Neuromyelitis Optica; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin Details
MBS-303 MBS-303 Phase 2 Clinical Beijing Mabworks Biotech Co Ltd Lymphoma, B-Cell Details
Divozilimab BCD-132 Phase 3 Clinical Biocad Scleroderma, Systemic; Multiple Sclerosis; Neuromyelitis Optica Details
TRS-005 TRS-005 Phase 1 Clinical Zhejiang Teruisi Pharmaceutical Inc Lymphoma, Non-Hodgkin Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message